Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Bafna Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹268.20
High
₹268.20
Price Summary
| Previous Close | ₹268.20 |
|---|---|
| Day's Range | ₹268.20 - ₹268.20 |
| Open | ₹268.20 |
| 52 Week Range | ₹78.18 - ₹262.91 |
| Volume | 593 |
| Market Cap | ₹0.00 |
| Previous Close | ₹273.15 |
|---|---|
| Day's Range | ₹273.15 - ₹273.15 |
| Open | ₹273.15 |
| 52 Week Range | ₹77.01 - ₹269.20 |
| Volume | 3,793 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.59 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -10.45 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | -4.43 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -2.99 |
| Trade Value ( ₹ in Lacs) | 10.36 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -10.45 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | -4.43 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -2.99 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 390.6 | 1458.57 |
| Expenses | N/A | N/A |
| PBT | 13.11 | 41.52 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 13.11 | 41.53 |
About Bafna Pharmaceuticals Ltd.
| Founded | 1995 |
|---|---|
| NSE Symbol | BAFNAPH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,67,870.32 | 1,950.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,20,945.52 | 8,322.85 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,906.63 | 5,019.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,818.07 | 8,820.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,673.63 | 1,469.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,346.37 | 1,116.25 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,639.01 | 2,376.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,086.80 | 1,090.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,193.79 | 2,474.45 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 98,733.25 | 569.80 | 0.00 - 0.00 |
No Records Found
Latest News
Trident Lifeline informs about earnings presentation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Trident Lifeline has informed that it enclosed Earnings Presentation for the Quarter ended 30th June, 2026 (Q1 & FY27).
The above information is a part of company’s filings submitted to BSE.
Kaya board approves unaudited standalone financial results
Amanta Healthcare informs about analyst meet
Kaya informs about completion of tenure of independent director
to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Kaya has informed that Om Prakash Manchanda (DIN: 02099404) has completed his first consecutive term of five years as an Independent Director of the Company on August 02, 2026. Consequently, he ceased to be a Director of the Company with effect from the end of the day on August 02, 2026. The Board of Directors and the Management of the Company place on record their sincere appreciation for the valuable guidance, support, and significant contributions made by Om Prakash Manchanda during his tenure with the Company. The details as required under SEBI LODR read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is given in Annexure A to this letter.
Park Medi World informs about outcome of board meeting
In continuation of its intimation dated July 29, 2026, and pursuant to the provisions of Regulations 30 and 33 of the Listing Regulations, Park Medi World has informed that the Board of Directors of Company in its meeting held today, Monday, August 03, 2026, has considered and approved the following items: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on June 30, 2026. The Financial Results along with the Limited Review Report are enclosed as Annexure-I. 2. Acquisition of ‘Mehar Hospital-Zirakpur’, owned and operated by Mehar Mediserve LLP. The details as required under the Listing Regulations read with SEBI circular HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, along with the press release towards the aforesaid acquisition are enclosed as Annexure -II. 3. Variation in the objects of the Initial Public Offer Proceeds as stated in the Prospectus dated December 12, 2025, subject to approval of the Shareholders by way of Postal Ballot and the notice for obtaining shareholders’ approval for the proposed Variation will be sent to the Shareholders of the Company and the Stock Exchanges in due course. Further details of the Proposed Variation will be set out in the explanatory statement forming part of the notice. The meeting of the Board of Directors of the Company commenced at 08:00 AM (IST) and concluded at 09:20 am (IST). The financial results will also be available on the Company's website at https://www.parkhospital.in/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Bafna Pharmaceuticals Ltd. is ₹268.20 as of 2026-08-03.
The market capitalisation of Bafna Pharmaceuticals Ltd. is ₹646.17 as of 2026-08-03.
The 1-year return of Bafna Pharmaceuticals Ltd. is 182.57% as of 2026-08-03.
The P/E ratio of Bafna Pharmaceuticals Ltd. is 42.73 as of 2026-08-04.
The 52-week high and low of Bafna Pharmaceuticals Ltd. are ₹262.91 and ₹78.18, respectively, as of 2026-08-03.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
